JP2004041195A5 - - Google Patents

Download PDF

Info

Publication number
JP2004041195A5
JP2004041195A5 JP2003169309A JP2003169309A JP2004041195A5 JP 2004041195 A5 JP2004041195 A5 JP 2004041195A5 JP 2003169309 A JP2003169309 A JP 2003169309A JP 2003169309 A JP2003169309 A JP 2003169309A JP 2004041195 A5 JP2004041195 A5 JP 2004041195A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
protein
amino acid
acid sequence
inhibitory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003169309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004041195A (ja
JP3935861B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003169309A priority Critical patent/JP3935861B2/ja
Priority claimed from JP2003169309A external-priority patent/JP3935861B2/ja
Publication of JP2004041195A publication Critical patent/JP2004041195A/ja
Publication of JP2004041195A5 publication Critical patent/JP2004041195A5/ja
Application granted granted Critical
Publication of JP3935861B2 publication Critical patent/JP3935861B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003169309A 1997-04-15 2003-06-13 新規蛋白質及びその製造方法 Expired - Lifetime JP3935861B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003169309A JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02
JP2003169309A JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP54374198A Division JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004381995A Division JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法

Publications (3)

Publication Number Publication Date
JP2004041195A JP2004041195A (ja) 2004-02-12
JP2004041195A5 true JP2004041195A5 (cg-RX-API-DMAC7.html) 2005-08-04
JP3935861B2 JP3935861B2 (ja) 2007-06-27

Family

ID=27525882

Family Applications (7)

Application Number Title Priority Date Filing Date
JP54374198A Expired - Lifetime JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法
JP2003169309A Expired - Lifetime JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP54374198A Expired - Lifetime JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Country Status (21)

Country Link
US (7) US7527790B2 (cg-RX-API-DMAC7.html)
EP (3) EP2336168A1 (cg-RX-API-DMAC7.html)
JP (7) JP3523650B2 (cg-RX-API-DMAC7.html)
KR (1) KR100496063B1 (cg-RX-API-DMAC7.html)
CN (1) CN1138786C (cg-RX-API-DMAC7.html)
AT (1) ATE328006T1 (cg-RX-API-DMAC7.html)
AU (1) AU735355B2 (cg-RX-API-DMAC7.html)
CA (2) CA2257247C (cg-RX-API-DMAC7.html)
CY (1) CY2010017I2 (cg-RX-API-DMAC7.html)
DE (2) DE69834699T3 (cg-RX-API-DMAC7.html)
DK (1) DK0911342T4 (cg-RX-API-DMAC7.html)
ES (1) ES2263204T5 (cg-RX-API-DMAC7.html)
FR (1) FR10C0048I2 (cg-RX-API-DMAC7.html)
HU (3) HU229476B1 (cg-RX-API-DMAC7.html)
IL (1) IL127115A (cg-RX-API-DMAC7.html)
LU (1) LU91759I2 (cg-RX-API-DMAC7.html)
NO (2) NO322632B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332995A (cg-RX-API-DMAC7.html)
PT (1) PT911342E (cg-RX-API-DMAC7.html)
RU (1) RU2238949C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998046644A1 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
WO1999058674A2 (en) * 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
WO2000024416A1 (en) 1998-10-28 2000-05-04 Snow Brand Milk Products Co., Ltd. Remedies for bone metabolic errors
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
WO2001062932A1 (en) † 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
MXPA05006147A (es) * 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (ru) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Способ профилактики рождения больных остеопетрозом детей
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP3561071B1 (en) * 2006-02-13 2020-12-16 Fluidigm Canada Inc. Gene expression assays conducted by elemental analysis
CA2651597C (en) 2006-05-12 2013-02-05 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
US20100105612A1 (en) 2006-10-11 2010-04-29 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
WO2008150025A1 (ja) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
CN108130327A (zh) 2007-10-11 2018-06-08 第三共株式会社 靶向破骨细胞相关蛋白Siglec-15的抗体
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
CN102361632A (zh) * 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
EP2377932B1 (en) 2009-04-09 2020-11-18 Daiichi Sankyo Company, Limited ANTI-Siglec-15 ANTIBODY
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
CA2813314A1 (en) 2010-10-05 2012-04-12 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤
CN104349785A (zh) * 2012-03-21 2015-02-11 达纳-法伯癌症研究所有限公司 人淋巴系器官源性抑制性基质细胞的分离和用途
US9464133B2 (en) 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP3030249B1 (en) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
JP6862542B2 (ja) * 2016-09-13 2021-04-21 イー アンド エス ヘルスケア カンパニー リミテッド チオレドキシン1に特異的に結合する単一クローン抗体およびその用途
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN112521466B (zh) * 2020-01-22 2022-06-17 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118119C (en) 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (ja) 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするcDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
EP0727211A1 (en) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規dna及びそれを用いた蛋白質の製造方法
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
WO1998028423A2 (en) 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
KR20010085996A (ko) 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Similar Documents

Publication Publication Date Title
AU2012351751B2 (en) Methods of purifying antibodies
US20200181287A1 (en) Methods of purifying bispecific antibodies
JP2026065087A (ja) 操作されたcd25ポリペプチドおよびその使用
JP2020505919A5 (cg-RX-API-DMAC7.html)
JP2007530435A5 (cg-RX-API-DMAC7.html)
JP2023509212A5 (cg-RX-API-DMAC7.html)
JP2009539348A5 (cg-RX-API-DMAC7.html)
RU2018119366A (ru) Мыши с гуманизированной легкой цепью
US11945839B2 (en) Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2023553694A5 (cg-RX-API-DMAC7.html)
CN118063620A (zh) 双特异性抗体
JP2025090679A5 (cg-RX-API-DMAC7.html)
US20260078202A1 (en) Orthogonal mutations for heterodimerization
JP5323710B2 (ja) ヒトに適合するモノクローナル抗体に使用するための方法
RU2004108115A (ru) Рекомбинантные антитела и композиции, а также способы их создания и использования
Schiffer Molecular anatomy and the pathological expression of antibody light chains
JP2008517605A5 (cg-RX-API-DMAC7.html)
RU98105631A (ru) Антитела против fas
Weidenhaupt et al. Functional mapping of conserved, surface‐exposed charges of antibody variable domains
JP4471721B2 (ja) 抗インターロイキン21受容体(il−21r)抗体および本抗体を産生するハイブリドーマ
AU2018244638B2 (en) Methods and kits for determining binding sites
JP2023540808A5 (cg-RX-API-DMAC7.html)
RU2729391C2 (ru) Моноклональное антитело, способное нейтрализовать биологическую активность интерферона бета-1а человека
CA3251683A1 (en) FELINE ANTIBODY LIBRARIES